Castle Biosciences, Inc. Share Price
Equities
CSTL
US14843C1053
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.24 USD | +0.21% |
|
+5.57% | +8.59% |
| 01-11 | Castle Biosciences 2025 total revenue expected to exceed $340 million | RE |
| 01-11 | Castle Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Year Ended Dec. 31, 2025 | CI |
| Capitalization | 1.23B 1.05B 972M 908M 1.69B 113B 1.79B 11.11B 4.41B 53.48B 4.62B 4.53B 195B | P/E ratio 2025 * |
-44.6x | P/E ratio 2026 * | -35.9x |
|---|---|---|---|---|---|
| Enterprise value | 1.23B 1.05B 972M 908M 1.69B 113B 1.79B 11.11B 4.41B 53.48B 4.62B 4.53B 195B | EV / Sales 2025 * |
3.67x | EV / Sales 2026 * | 3.75x |
| Free-Float |
96.78% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Castle Biosciences, Inc.
| 1 day | +0.21% | ||
| 1 week | +5.57% | ||
| Current month | +8.59% | ||
| 1 month | +5.07% | ||
| 3 months | +74.69% | ||
| 6 months | +151.43% | ||
| Current year | +8.59% |
| 1 week | 39.74 |  | 43.01 |
| 1 month | 37.29 | | 43.01 |
| Current year | 37.29 | | 43.01 |
| 1 year | 14.59 | | 43.01 |
| 3 years | 9.26 | | 43.01 |
| 5 years | 9.26 | | 107.69 |
| 10 years | 9.26 | | 107.69 |
| Manager | Title | Age | Since |
|---|---|---|---|
Derek Maetzold
CEO | Chief Executive Officer | 64 | 31/08/2007 |
Franklin Stokes
DFI | Director of Finance/CFO | 56 | 30/11/2017 |
| Chief Tech/Sci/R&D Officer | - | 30/11/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Derek Maetzold
BRD | Director/Board Member | 64 | 31/08/2007 |
Daniel Bradbury
CHM | Chairman | 64 | 31/08/2014 |
G. Cole
BRD | Director/Board Member | 70 | 05/12/2018 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +4.78% | 0.02% | 300 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.21% | +5.57% | +59.40% | +56.44% | 1.23B | |
| -2.16% | +2.33% | +136.11% | +239.90% | 14.78B | |
| -0.86% | -0.86% | -8.07% | +6.12% | 14.4B | |
| -2.15% | -6.65% | - | - | 7.05B | |
| -0.99% | -3.68% | -12.15% | +0.11% | 6.31B | |
| -0.33% | -1.80% | -31.13% | -41.52% | 4.65B | |
| +0.49% | +5.07% | -30.85% | +23.67% | 4.48B | |
| +1.28% | +1.14% | -6.35% | -42.99% | 3.06B | |
| -3.49% | +9.06% | +50.20% | -53.30% | 2.83B | |
| Average | -0.89% | +0.90% | +19.65% | +23.55% | 6.53B | |
| Weighted average by Cap. | -1.20% | +0.43% | +33.48% | +64.46% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 336M 286M 265M 247M 461M 30.87B 489M 3.03B 1.2B 14.57B 1.26B 1.23B 53.01B | 329M 279M 259M 242M 451M 30.18B 478M 2.96B 1.17B 14.25B 1.23B 1.21B 51.84B |
| Net income | -26.1M -22.19M -20.57M -19.22M -35.84M -2.4B -37.99M -235M -93.34M -1.13B -97.85M -95.85M -4.12B | -32.25M -27.43M -25.42M -23.76M -44.29M -2.96B -46.94M -291M -115M -1.4B -121M -118M -5.09B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 42.24 $ | +0.21% | 371,273 |
| 22/01/26 | 42.15 $ | +2.86% | 251,582 |
| 21/01/26 | 40.98 $ | +0.29% | 279,315 |
| 20/01/26 | 40.86 $ | +2.12% | 298,793 |
| 16/01/26 | 40.01 $ | -1.82% | 289,656 |
Delayed Quote Nasdaq, January 23, 2026 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CSTL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition